Safety and clinical efficacy of immune checkpoint inhibitors in advanced gastric cancer in the real world.

ABSTRACT:

Background

To evaluate the clinical efficacy and safety of immune checkpoint inhibitors in patients with advanced gastric cancer in the real world.

Methods

The retrospective analysis was conducted on the clinical records of 402 patients with advanced gastric cancer who were admitted to the Nanjing Drum Tower Hospital between December 2017 and April 2022 and who had received immunotherapy. Observation target: drug use, treatment, adverse reaction type and grade, objective response rate (ORR), disease control rate (DCR), progression free survival (PFS), and overall survival (OS).

Results

By retrospectively analyzing the data of patients with advanced gastric cancer treated with ICIs previously admitted to our medical center, we found some clinical characteristic factors

SUBMITTER: Hao W 

PROVIDER: S-EPMC11001672 | biostudies-literature | 2024 Apr

REPOSITORIES: biostudies-literature